NALM6 Doxorubicin/ADR Resistant Cell Line

Product Name	NALM6 Doxorubicin/ADR Resistant Cell Line
Cat.No	RG-499
Size	1*10^6 cells/vial
Description	NALM6 Doxorubicin Resistant Cell Line was developed by stepwise increased concentrations of Doxorubicin. Cells were continuously maintained in Doxorubicin, with treatments beginning at the initial IC50 of the respective parent cell lines. NALM6/ADR cell line, is an Adriamycin (doxorubicin)-selected, P-gp-positive (P-glycoprotein 1) variant of the NALM6 cell line.
Tissue	Peripheral blood
Species	Human
Disease	Acute lymphoblastic leukemia ALL
Parental Cell Line	NALM6
Biosafety Level	BSL 1. Runtogen determines the biosafety level of a material based on our risk assessment as guided by the current edition of Biosafety in Microbiological and Biomedical Laboratories (BMBL), U.S. Department of Health and Human Services.
Resistance	Adriamycin (doxorubicin)
Morphology	Lymphoblast-like, Suspension
Culture Method	RPMI1640+10%FBS+70nM Doxorubicin
Shipping	Cryopreserved cells are shipped with dry ice
Storage	Upon arrival, Check all containers for leakage or breakage. Remove the frozen cells from the dry ice packaging and immediately place the cells at a temperature below -130°C, preferably in liquid nitrogen vapor, until ready for use.
Warranty	Our Cell Line is warranted for 30 days from the date of shipment, provided that the customer has stored and handled the product according to the information included on the product datasheet, website, and COA.
Disclaimers	This cell line is intended for laboratory research use only. It is not intended for any human or animal therapeutic use, any animal or human consumption, or any diagnostic use. Any proposed commercial use is prohibited without a license from Runtogen.

NALM6 Doxorubicin/ADR Resistant Cell Line

Online Inquiry

Online Inquiry